Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Reverse Transcriptase Inhibitors
100%
Replication Capacity
100%
Inhibitor Drug
100%
Drug Resistance mutations
100%
Phenotypic Susceptibility
100%
Resistance mutations
75%
Decreased Susceptibility
75%
Reverse Transcriptase
75%
Virus
50%
Nucleoside Reverse Transcriptase Inhibitors
50%
Genetic Resistance
50%
Virus Strains
50%
Increased Vulnerability
50%
Zidovudine
50%
Lamivudine
50%
Stavudine
50%
Tenofovir
50%
Abacavir
50%
M184V
50%
Didanosine
50%
Site-directed mutagenesis
25%
HIV Patients
25%
Quantitative PCR
25%
Amino Acids
25%
Clinical Practice
25%
Drug Resistance
25%
Recombinant Virus
25%
HIV Viral Load
25%
Resistance Phenotypes
25%
Fixed-dose Combination
25%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
25%
Recombinant Strain
25%
Interaction Patterns
25%
Nonnucleoside Reverse Transcriptase Inhibitor Resistance
25%
K103N
25%
Treatment-experienced Patients
25%
Complex Resistance
25%
Combination pill
25%
Pharmacology, Toxicology and Pharmaceutical Science
RNA Directed DNA Polymerase Inhibitor
100%
RNA Directed DNA Polymerase
100%
Drug Resistance
100%
Human Immunodeficiency Virus 1
100%
HIV
50%
Virus Strain
50%
Tenofovir
50%
Zidovudine
50%
Nonnucleoside Reverse Transcriptase Inhibitor
50%
Didanosine
50%
Stavudine
50%
Abacavir Plus Lamivudine
50%
Amino Acid
25%
Site-Directed Mutagenesis
25%
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Drug Resistance
100%
Reverse Transcriptase
100%
Virus Strain
22%
Tenofovir
22%
Blood Plasma
11%
Human Immunodeficiency Virus
11%
Site Directed Mutagenesis
11%
Recombinant Virus
11%
Reverse Transcription Polymerase Chain Reaction
11%